# Cortisone Shots Market

> Cortisone Shots Market Research Report Information: By Type (Articular or Joint Injections, Epidural Steroid Injection, Trigger Point Injection), Indication (Rheumatoid Arthritis, Psoriatic Arthritis, Tendinitis, Allergic Reaction), End User - Global Forecast till 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 7.38%
- **2024:** $ 2,142.97 Million
- **2025:** $ 2,325.68 Million
- **2035:** $ 4,710.17 Million
- **Key Players:** Pfizer (US), Merck & Co. (US), Bristol-Myers Squibb (US), Sanofi (FR), Amgen (US), AbbVie (US), Hikma Pharmaceuticals (GB), Mylan (US), Teva Pharmaceutical Industries (IL)

**Report ID:** MRFR/Pharma/3419-HCR · **Pages:** 110 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** May 15, 2026

**URL:** https://www.marketresearchfuture.com/reports/cortisone-shots-market-4847

---

## Market Summary

## **Global Cortisone Shots Market Overview**

The Cortisone Shots Market Size was valued at USD 2.74 Billion in 2023. The Global Cortisone Shots industry is projected to grow from USD 2.95 Billion in 2024 to USD 4.93 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.85% during the forecast period (2024 - 2032).

Also known as cortisone injections, cortisone shots are used to relieve pain and inflammation in case of injury to the joints or other parts of the body. They are most commonly used to treat inflammation at the joints such as knee, spine, ankle, elbow, hip, shoulder and wrist, and are usually administered in a clinical setting with the doctor’s approval. Cortisone injections have a similar anti-inflammatory action to other corticosteroids. It is composed of corticosteroid medication and a local anesthetic. Due to the potential side effects of cortisone shots, the number of doses administered to a patient is limited.

Major indications for the use of cortisone shots are arthritis, skin diseases, tendinitis, and other sport injuries.

In November 2022,  Anika Therapeutics, Inc., a worldwide firm specializing in preserving joints, has reported that Cingal® successfully achieved its main objective in a Phase III Study (Cingal 19-01). The study showed that Cingal® was superior to triamcinolone hexacetonide (TH) steroid alone in the 26 weeks following therapy. The Cingal 19-01 Phase III study is the third fully completed Phase III research of Cingal. It has shown superiority above both its active ingredients and placebo, as indicated by prior studies.

Throughout the three Phase III studies that have been completed, Cingal exhibited an average pain improvement of 71% compared to the initial condition. Additionally, an average of 91% of the participants who received Cingal were considered to be Responders. Cingal is a composite product consisting of cross-linked hyaluronic acid (HA) that has been scientifically demonstrated to offer enduring pain relief for a period of at least 6 months. Additionally, it contains a TH steroid that provides rapid but temporary pain relief.

Both components of Cingal have received approval for commercial distribution in the United States, specifically for the treatment of knee osteoarthritis (OA) pain. Cingal is presently distributed in over 35 countries worldwide, excluding the United States. Anika plans to collaborate with the U.S. Food and Drug Administration (FDA) in the upcoming months to discuss the necessary actions for obtaining regulatory approval in the United States. Simultaneously, Anika is investigating the possibility of promoting Cingal through business collaborations in the United States and specific Asian markets.

These endeavors will provide information for determining the further actions, including whether and in what manner to proceed with another clinical trial in the United States.

## Cortisone Shots Market Trends

Rising prevalence of chronic diseases such as [rheumatoid arthritis](../../../reports/rheumatoid-arthritis-market-1658), tendinitis, and bursitis, increasing number of injuries to the joints, muscles and tendon, and the presence of key players in the market are important driver that accelerate the growth of the market. Rising geriatric population is another key driver for the market growth due to increasing prevalence of arthritis among the elderly. However, cortisone shots exhibit a number of disadvantages such as damage to the tendons, ligaments, and articular cartilage, thus restricting the growth of the market.

World Health Organization, Centers for Disease Control and Prevention (CDC), European Society of Clinical Microbiology and Infectious Diseases, U.S. National Library of Medicine, National Organization for Rare Disorders, The International Society for Human and Animal Mycology, Expert Interview Market Research Future Analysis, Annual report, White paper, Company Presentation

**Research Methodology **

Source: World Health Organization, Centers for Disease Control and Prevention, European Society of Clinical Microbiology and Infectious Diseases, U.S. National Library of Medicine, National Organization for Rare Disorders, The American Autoimmune Related Diseases Association, The International Society for Human and Animal Mycology, Expert Interview Market Research Future Analysis, Annual report, White paper, Company Presentation

**Segments  **    

The global cortisone shots market is segmented on the basis of type, indication, and end user.

On the basis of type, market is segmented into articular or joint injections, epidural steroid injection, trigger point injection, and others.

On the basis of indication, the market is segmented into rheumatoid arthritis, psoriatic arthritis, bursitis, allergic reaction, skin conditions, and others.

On the basis of end user, the market is segmented into hospitals, clinics, sport medicine centers, pharmaceutical companies, and others.

**Regional Analysis of the Global Cortisone Shots Market  **

America acquires the first position in the market for cortisone shots owing to the rising prevalence of various types of allergies, arthritis, tendinitis, and others, and rising demand for corticosteroid injection in the U.S. According to the Center for Disease Control and Prevention, an estimated 78 million i.e. 26% of the U.S. adults aged 18 years or older are projected to have doctor-diagnosed arthritis by 2040. Additionally, the prevalence of tendinitis among athletes is found to be increasing from last few years in the U.S.

Europe is the second largest market for cortisone shots owing to the rising prevalence of rheumatoid arthritis in European countries, and availability of funds for research and development activities. Also, rising prevalence of allergic conditions such as asthma, food allergy, and anaphylaxis, increasing demand for diagnostic services and rising awareness about the use of cortisone injections for the treatment of tendinitis fuels the market growth.

The market in Asia Pacific is expected to grow at the fastest pace and is driven by the rising prevalence of diabetes, obesity, which act as risk factors for rheumatoid and osteoarthritis which is further posed to propel the growth of the market. Furthermore, rising awareness about sport injuries and the use of cortisone shots for their treatment, influences the growth of the market positively.

The Middle East & Africa also show a steady rise in the market owing to high prevalence of chronic diseases such as obesity and diabetes, and improving healthcare infrastructure. Increasing demand for new treatment options for sport injuries also influences the market growth in the Middle East & African countries.

**Key Players in the Global Cortisone Shots Market    **

Some of the key players in this market are Merck & Co., Inc. (U.S.), [Pfizer](https://www.pfizer.com/products/product-list) (U.S.), Bristol-Myers Squibb Company (U.S.), Novartis AG (Germany), GlaxoSmithKline (U.S.), Pharmascience Inc. (U.S.), Farmabios SPA (Italy), AdvaCare Pharma (U.S.), and others.

**Intended Audience**

## Market Drivers

### Aging Population

The aging population is a significant driver of the Global Cortisone Shots Market Industry. As individuals age, they are more likely to develop chronic conditions that require management through cortisone injections. The demographic shift towards an older population is evident in many countries, leading to an increased demand for effective pain relief solutions. This trend is particularly pronounced in developed nations, where healthcare systems are adapting to cater to the needs of older adults. Consequently, the market is poised for growth, with projections indicating a substantial increase in demand for cortisone shots in the coming years.

### Market Growth Projections

The Global Cortisone Shots Market Industry is projected to experience substantial growth over the next decade. With a market value anticipated to reach 5.85 USD Billion by 2035, the industry is on a trajectory of expansion. This growth is underpinned by various factors, including the rising prevalence of chronic diseases, advancements in medical technology, and increasing patient awareness. The compound annual growth rate of 6.42% from 2025 to 2035 indicates a robust market environment, suggesting that cortisone shots will continue to play a vital role in pain management and treatment strategies globally.

### Growing Awareness and Acceptance

There is a notable increase in awareness and acceptance of cortisone shots among patients and healthcare professionals, which is positively impacting the Global Cortisone Shots Market Industry. Educational initiatives and patient advocacy groups are playing a crucial role in informing individuals about the benefits and risks associated with cortisone injections. This growing understanding is leading to more patients seeking these treatments for pain management. As acceptance rises, the market is expected to grow, with estimates suggesting a market value of 5.85 USD Billion by 2035, indicating a robust future for cortisone shot therapies.

### Regulatory Support and Guidelines

Regulatory support and updated clinical guidelines are fostering growth in the Global Cortisone Shots Market Industry. Health authorities are increasingly recognizing the therapeutic benefits of cortisone injections, leading to the establishment of clear guidelines for their use. This regulatory backing not only enhances the credibility of cortisone shots as a treatment option but also encourages healthcare providers to incorporate them into their practice. As a result, the market is likely to benefit from increased utilization and acceptance, further solidifying its position in the healthcare landscape.

### Advancements in Medical Technology

Technological advancements in the administration of cortisone shots are significantly influencing the Global Cortisone Shots Market Industry. Innovations such as ultrasound-guided injections enhance precision and reduce complications, leading to improved patient outcomes. These advancements not only increase the efficacy of cortisone shots but also encourage healthcare providers to adopt these methods more widely. As a result, the market is likely to see a surge in demand, with a projected compound annual growth rate of 6.42% from 2025 to 2035. This growth reflects the ongoing evolution of treatment methodologies in the healthcare sector.

### Rising Prevalence of Chronic Conditions

The Global Cortisone Shots Market Industry is experiencing growth due to the increasing prevalence of chronic conditions such as arthritis, asthma, and autoimmune disorders. As these conditions become more common, the demand for effective treatment options rises. Cortisone shots, known for their anti-inflammatory properties, are often utilized to manage pain and inflammation associated with these ailments. For instance, arthritis affects millions globally, leading to a heightened need for cortisone injections. This trend is expected to contribute to the market's expansion, with projections indicating a market value of 2.95 USD Billion in 2024.

## Future Outlook

The Cortisone Shots Market is projected to grow at a 7.38% CAGR from 2025 to 2035, driven by increasing demand for pain management and advancements in injection techniques.

**New opportunities:**

- Development of mobile app platforms for patient scheduling and education Expansion of [telehealth](https://www.marketresearchfuture.com/reports/telehealth-market-900) services for remote cortisone shot consultations Partnerships with sports organizations for targeted pain management programs

By 2035, the Cortisone Shots Market is expected to achieve robust growth and enhanced service delivery.

## Segment Insights

### By Application: Orthopedic (Largest) vs. Dermatology (Fastest-Growing)

The Cortisone Shots Market showcases a varied distribution of market share across its application segments. Orthopedic applications hold the largest share as cortisone shots are primarily used for treating joint pain and inflammation, providing significant relief to patients with arthritis and similar conditions. Following closely, Dermatology is witnessing a rapid growth trend due to the increasing prevalence of skin disorders, including psoriasis and eczema, driving demand for cortisone injections. Growth in the Cortisone Shots Market is propelled by rising awareness of non-surgical pain management solutions across the healthcare landscape. The orthopedic segment benefits from a growing aging population actively seeking effective treatments for joint diseases, whereas dermatology is emerging as the fastest-growing application segment, fueled by advancements in drug formulations and a heightened focus on aesthetic treatments that require corticosteroid injections.

Orthopedic (Dominant) vs. Dermatology (Emerging)

Within the Cortisone Shots Market, the orthopedic segment stands out as the dominant application, primarily driven by its role in managing orthopedic conditions such as arthritis, tendonitis, and bursitis. This segment addresses the needs of a substantial patient population suffering from musculoskeletal disorders. In contrast, the dermatology segment is recognized as emerging, gaining traction due to increasing cases of skin conditions requiring intervention. The growth in dermatological applications is significantly impacted by the rise of chronic skin ailments and an increasing acceptance of cortisone shots as part of treatment regimens. This juxtaposition reveals a dynamic market where traditional therapies in orthopedics interface with the innovative behavioral shift towards dermatological treatments.

### By Administration Route: Intra-articular (Largest) vs. Intramuscular (Fastest-Growing)

In the Cortisone Shots Market, the 'By Administration Route' segment is prominently led by intra-articular injections, which capture the largest market share due to their targeted delivery to joints, ensuring effective pain relief for conditions like arthritis. Intramuscular administration follows, providing broader applicability across various medical scenarios, while intradermal and subcutaneous routes, though vital, hold smaller shares as they are less frequently used for cortisone delivery. The distribution reflects the preference of healthcare professionals and patients towards methods yielding faster and more efficient outcomes.

Administration Routes: Intra-articular (Dominant) vs. Intramuscular (Emerging)

Intra-articular administration is recognized as the dominant route for cortisone shots, particularly in treating joint pain and inflammation. Its targeted approach delivers medication directly into the affected area, leading to faster therapeutic effects and reduced systemic side effects, making it a preferred choice for many practitioners. On the other hand, the intramuscular route is emerging rapidly due to its versatility and ease of administration. It is gaining popularity among clinicians for its ability to deliver larger doses efficiently and its application in various inflammatory conditions. Both routes are crucial to the market, but intra-articular remains the go-to for joint-specific treatments.

### By Patient Demographics: Age Group (Largest) vs. Activity Level (Fastest-Growing)

In the Cortisone Shots Market, patient demographics play a vital role in market share distribution. Age groups, particularly the older demographic, hold a significant share due to their higher prevalence of joint-related ailments. Following closely are younger adults who seek cortisone shots for sports injuries and chronic pain management. Gender distribution indicates that females are more likely to seek cortisone injections, primarily due to higher rates of autoimmune diseases. Meanwhile, activity level influences market share, where less active individuals tend to require cortisone treatments more frequently than those with a higher activity level.

Age Group (Dominant) vs. Activity Level (Emerging)

The aging population is the dominant force in the Cortisone Shots Market, largely because age correlates with increased susceptibility to conditions like arthritis and tendinitis. This demographic segment benefits from the prolonged medical use of cortisone shots as a treatment option for inflammation and pain. In contrast, the emerging activity level segment is rapidly gaining traction, particularly among younger adults engaged in sports. Increased participation in physical activities leads to a corresponding increase in injuries requiring cortisone treatments. As fitness trends continue to rise, this segment's importance is projected to grow, highlighting the need for targeted marketing strategies addressing the unique needs of active individuals.

### By Formulation Type: Aqueous (Largest) vs. Suspension (Fastest-Growing)

In the Cortisone Shots Market, the formulation type segment is characterized by a diverse distribution among various options, including Aqueous, Suspension, and Emulsion. Aqueous formulations lead the market due to their established efficacy and ease of administration, capturing the largest share. Conversely, suspensions are rapidly gaining traction, particularly among physicians and patients who prefer their unique delivery capabilities. Emulsions, while present, hold a smaller share but play a relevant role for specific applications.

Aqueous (Dominant) vs. Suspension (Emerging)

Aqueous formulations dominate the Cortisone Shots Market, offering benefits such as quick absorption and minimal side effects, establishing their position as a preferred choice for practitioners. They are particularly advantageous in acute cases where immediate relief is necessary. In contrast, suspension formulations are emerging, characterized by their extended release profile, which appeals to patients requiring long-term management of inflammatory conditions. As awareness grows regarding the advantages of suspensions, innovations in formulation and delivery are expected to drive their broader adoption, positioning them as a significant alternative to traditional aqueous options.

### By Treatment Duration: Short-term (Largest) vs. Long-term (Fastest-Growing)

The treatment duration segment in the cortisone shots market showcases a diverse distribution of market share among short-term, long-term, and chronic treatment options. Short-term cortisone shots have emerged as the dominant choice for patients experiencing acute conditions like arthritis or tendinitis, owing to their immediate relief capabilities. Long-term options, while initially trailing in prevalence, have gained traction as healthcare providers emphasize sustained relief in chronic pain management, leading to a notable shift in market preference over the recent years.

Long-term (Dominant) vs. Chronic (Emerging)

Long-term cortisone injections are increasingly recognized for their ability to provide consistent relief for chronic conditions such as autoimmune diseases and persistent joint pain, enabling patients to maintain a better quality of life. This segment is characterized by a growing acceptance within medical practices, driven by a strong emphasis on managing chronic conditions effectively. Conversely, chronic treatment options are emerging as a vital part of pain management strategies, appealing to a niche market that requires prolonged interventions. As patient awareness increases and treatment protocols evolve, the chronic segment is positioned to experience significant growth, catering to those seeking long-term solutions.

## Regional Market Share Analysis

### North America : Market Leader in Cortisone Shots

North America continues to lead the Cortisone Shots market, holding a significant share of approximately 1071.49 million in 2024. The growth is driven by increasing incidences of inflammatory conditions, advancements in healthcare infrastructure, and a robust regulatory framework that supports innovative therapies. The demand for effective pain management solutions is also on the rise, further propelling market expansion in this region. The competitive landscape is characterized by major players such as Pfizer, Merck & Co., and AbbVie, who are actively involved in research and development to enhance product offerings. The U.S. remains the largest market, benefiting from high healthcare expenditure and a well-established distribution network. The presence of leading pharmaceutical companies ensures a steady supply of Cortisone Shots, catering to the growing patient population.

### Europe : Emerging Market with Growth Potential

Europe's Cortisone Shots market is valued at approximately 642.89 million, reflecting a growing demand driven by an aging population and increasing prevalence of chronic diseases. Regulatory bodies are actively promoting the use of corticosteroids for various inflammatory conditions, which is expected to further boost market growth. The region is witnessing a shift towards more personalized medicine, enhancing treatment efficacy and patient outcomes. Leading countries such as Germany, France, and the UK are at the forefront of this market, supported by strong healthcare systems and innovative research initiatives. Key players like Sanofi and Bristol-Myers Squibb are investing in new product developments and strategic partnerships to strengthen their market position. The competitive landscape is evolving, with a focus on improving patient access to Cortisone Shots across Europe.

### Asia-Pacific : Rapidly Growing Market Segment

The Asia-Pacific region is witnessing a burgeoning demand for Cortisone Shots, with a market size of approximately 357.89 million. Factors such as rising healthcare awareness, increasing disposable incomes, and a growing elderly population are driving this growth. Additionally, favorable government initiatives aimed at improving healthcare access are expected to further enhance market dynamics in the coming years. Countries like China and India are leading the market, supported by expanding healthcare infrastructure and a rising prevalence of chronic diseases. The competitive landscape includes key players such as Amgen and Hikma Pharmaceuticals, who are focusing on expanding their product portfolios and enhancing distribution channels. The region's market is characterized by a mix of local and international players, contributing to a dynamic competitive environment.

### Middle East and Africa : Emerging Market with Challenges

The Middle East and Africa (MEA) region represents a smaller segment of the Cortisone Shots market, valued at approximately 70.7 million. The growth in this region is hindered by limited healthcare infrastructure and varying regulatory environments. However, increasing awareness of chronic diseases and the need for effective treatment options are driving demand for Cortisone Shots. Government initiatives aimed at improving healthcare access are expected to support market growth in the future. Countries like South Africa and the UAE are leading the market, with a focus on enhancing healthcare services and increasing patient access to medications. The competitive landscape is evolving, with both local and international players striving to establish a foothold in this emerging market. Key players are exploring partnerships and collaborations to navigate the unique challenges of the region.

## Competitive Benchmarking

The Cortisone Shots Market is characterized by a competitive landscape that is increasingly shaped by innovation, strategic partnerships, and regional expansion. Key players such as Pfizer (US), Merck & Co. (US), and AbbVie (US) are actively pursuing strategies that enhance their market positioning. Pfizer (US) has focused on expanding its product portfolio through research and development, particularly in the area of biologics, which may offer more targeted therapies. Merck & Co. (US) appears to be leveraging its extensive distribution network to optimize supply chains, ensuring that its cortisone products are readily available across various regions. AbbVie (US), on the other hand, has been investing in digital transformation initiatives to streamline operations and improve patient engagement, which collectively shapes a competitive environment that is dynamic and responsive to market needs.The business tactics employed by these companies include localizing manufacturing to reduce costs and enhance supply chain efficiency. The market structure is moderately fragmented, with several players vying for market share, yet the influence of major companies remains substantial. This competitive structure allows for a diverse range of products and services, catering to varying patient needs while fostering innovation through competition.
In November Merck & Co. (US) announced a strategic partnership with a leading telehealth provider to enhance patient access to cortisone shot consultations. This move is significant as it aligns with the growing trend of digital health solutions, potentially increasing patient adherence to treatment protocols and improving overall outcomes. Such partnerships may also facilitate better data collection and analysis, which could inform future product development.
In October AbbVie (US) launched a new formulation of its cortisone injection, which reportedly offers a longer duration of action. This development is crucial as it addresses a common patient concern regarding the frequency of injections, thereby enhancing patient satisfaction and compliance. The introduction of this product may also position AbbVie favorably against competitors, as it demonstrates a commitment to innovation and responsiveness to patient needs.
In September Pfizer (US) expanded its manufacturing capabilities in Europe, aiming to increase production capacity for its cortisone products. This expansion is indicative of the company's strategy to meet rising global demand while ensuring supply chain reliability. By bolstering its manufacturing footprint, Pfizer may enhance its competitive edge, particularly in regions experiencing growth in cortisone shot utilization.
As of December current trends in the Cortisone Shots Market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence (AI) in operations. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in navigating complex market dynamics. Looking ahead, competitive differentiation is likely to evolve, shifting from price-based competition to a focus on innovation, technology, and supply chain reliability. This transition may ultimately lead to improved patient outcomes and a more sustainable market environment.

## Report Scope

| MARKET SIZE 2024 | 2142.97(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 2325.68(USD Million) |
| MARKET SIZE 2035 | 4710.17(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 7.38% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Pfizer (US), Merck & Co. (US), Bristol-Myers Squibb (US), Sanofi (FR), Amgen (US), AbbVie (US), Hikma Pharmaceuticals (GB), Mylan (US), Teva Pharmaceutical Industries (IL) |
| Segments Covered | Application, Route of Administration, Formulation Type, Patient Demographics, Distribution Channel |
| Key Market Opportunities | Growing demand for minimally invasive treatments drives innovation in the Cortisone Shots Market. |
| Key Market Dynamics | Rising demand for cortisone shots drives innovation and competition among pharmaceutical manufacturers and healthcare providers. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the current market valuation of the Cortisone Shots Market?**
A: The Cortisone Shots Market was valued at approximately 2142.97 USD Million in 2024.

**Q: What is the projected market valuation for the Cortisone Shots Market in 2035?**
A: The market is projected to reach approximately 4710.17 USD Million by 2035.

**Q: What is the expected CAGR for the Cortisone Shots Market during the forecast period 2025 - 2035?**
A: The expected CAGR for the Cortisone Shots Market during the forecast period 2025 - 2035 is 7.38%.

**Q: Which companies are considered key players in the Cortisone Shots Market?**
A: Key players in the market include Pfizer, Merck & Co, Bristol-Myers Squibb, Sanofi, Amgen, AbbVie, Hikma Pharmaceuticals, Mylan, and Teva Pharmaceutical Industries.

**Q: What are the primary applications of cortisone shots in the market?**
A: The primary applications include Orthopedic, Dermatology, Rheumatology, Pulmonology, and Ophthalmology.

**Q: How does the market segment by administration route for cortisone shots?**
A: The market segments by administration route include Intra-articular, Intramuscular, Intradermal, and Subcutaneous.

**Q: What demographic factors are considered in the Cortisone Shots Market?**
A: Demographic factors include Age Group, Gender, Health Status, and Activity Level.

**Q: What are the different formulation types available in the Cortisone Shots Market?**
A: Formulation types include Aqueous, Suspension, and Emulsion.

**Q: How is the treatment duration categorized in the Cortisone Shots Market?**
A: Treatment duration is categorized into Short-term, Long-term, and Chronic.

**Q: What was the market valuation for the Orthopedic application segment in 2024?**
A: The market valuation for the Orthopedic application segment was approximately 600.0 USD Million in 2024.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/cortisone-shots-market-4847*